Top-News

TapImmune News

Keine aktuellen Kursdaten verfügbar
WKN: A2AR2W
ISIN: US8760334081
US-Symbol: TPIV
Typ: Aktie

TapImmune News

03.11.16 - PR Newswire
TapImmune Approved for Listing on the Nasdaq Capital Market
TapImmune Approved for Listing on the Nasdaq Capital Market PR Newswire
01.11.16 - PR Newswire
TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine
TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine Initiation of Company-​Sponsored Phase 2 Clinical Trials will start early 2017 PR Newswire
05.10.16 - PR Newswire
TapImmune President Dr. John Bonfiglio to Present at BioNetwork Partnering Summit on October 5, 2016
TapImmune President Dr. John Bonfiglio to Present at BioNetwork Partnering Summit on October 5, 2016 PR Newswire
15.09.16 - PR Newswire
TapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
TapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market PR Newswire
06.09.16 - PR Newswire
MicroCap Review Magazine Fall 2016 Issue Now Available
MicroCap Review Magazine Fall 2016 Issue Now Available The Digital Issue of the Fall 2016 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be ...
06.09.16 - PR Newswire
TapImmune Issues Update: Multiple Phase 2 Trials, over $9 Million in New Funding & NASDAQ Uplisting Application
TapImmune Issues Update: Multiple Phase 2 Trials, over $9 Million in New Funding & NASDAQ Uplisting Application PR Newswire
06.09.16 - PR Newswire
MicroCap Review Magazine Fall 2016 Issue Now Available
MicroCap Review Magazine Fall 2016 Issue Now Available The Digital Issue of the Fall 2016 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be ...
25.08.16 - PR Newswire
TapImmune Appoints Michael J. Loiacono as Chief Financial Officer
TapImmune Appoints Michael J. Loiacono as Chief Financial Officer Accomplished Financial Director & CFO of Public Companies PR Newswire
11.08.16 - PR Newswire
TapImmune Enters into Definitive Agreements to Raise $8.5 Million From the Exercise of Outstanding Warrants and in a Private Placement from New Investors
TapImmune Enters into Definitive Agreements to Raise $8.5 Million From the Exercise of Outstanding Warrants and in a Private Placement from New Investors Company has ...
19.07.16 - PR Newswire
TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer
TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer PR Newswire
21.06.16 - PR Newswire
TapImmune Doses First Patient in Its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200
TapImmune Doses First Patient in Its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200 Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in ...
07.06.16 - PR Newswire
TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine
TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine Agreement Will Allow for the Transfer of IND from Mayo to ...
06.06.16 - PR Newswire
TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016
TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016 PR Newswire
27.05.16 - PR Newswire
TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City
TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City PR Newswire
28.04.16 - PR Newswire
TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016 PR Newswire
21.04.16 - PR Newswire
TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute PR Newswire
07.04.16 - PR Newswire
TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine PR Newswire
14.03.16 - PR Newswire
TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016
TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016 PR Newswire
18.02.16 - PR Newswire
TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart - Next-Generation T-Cell Vaccine
TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart - Next-​Generation T-Cell Vaccine PR Newswire
10.02.16 - PR Newswire
TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care
TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care PR Newswire

Newssuche

Videos

newspaper
18.04.24
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »